CREATE Medicines is pioneering multi-immune programming with its versatile in vivo CAR platform. Our proprietary mRNA-LNP CARs and targeted receptor/LNP technologies enable direct programming of T cells, NK cells, and myeloid cells within the body. CREATE’s in vivo CAR products have demonstrated first-in-human evidence of uptake, expression, and tolerable repeat dosing.
What sets CREATE apart:
- Proprietary receptor and RNA engineering, including retrotransposon-mediated stability options
- First-in-human clinical data confirming mechanism of action
- Multilineage programming across immune cell types (T, NK, myeloid)
- Demonstrated tolerability with repeat dosing
